We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · April 08, 2022

CDK4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer With Germline Pathogenic Variants in DNA Repair–Related Genes

JCO Precision Oncology


Additional Info

Disclosure statements are available on the authors' profiles:

JCO Precision Oncology
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair-Related Genes
JCO Precis Oncol 2022 Mar 01;6(2022)e2100140, L Bruno, A Ostinelli, F Waisberg, D Enrico, C Ponce, S Rivero, A Blanco, M Zarba, M Loza, V Fabiano, M Amat, MT Pombo, L Noro, M Chacón, F Coló, R Chacón, J Nadal, A Nervo, V Costanzo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading